Evidence map›Paper›PMID 28146423›Full record

ArticleOncotarget2017

E2F-1 targets miR-519d to regulate the expression of the ras homolog gene family member C.

Xiu-Bo Sang, Zhi-Hong Zong, Li-Li Wang, Dan-Dan Wu, Shuo Chen, Bo-Liang Liu, Yang Zhao

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Role of RhoC in cancer cell migration.Cancer cell international · 2021
    Review
  5. Article
  6. Review
  7. Review
  8. Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xiu-Bo SangDepartment of Gynecology, The First Affiliated Hospital of China Medical University, Shenyang 110001, P. R. China.
Zhi-Hong ZongDepartment of Biochemistry and Molecular Biology, College of Basic Medicine, China Medical University, Shenyang 110001, P. R. China.
Li-Li WangDepartment of Gynecology, The First Affiliated Hospital of China Medical University, Shenyang 110001, P. R. China.
Dan-Dan WuDepartment of Gynecology, The First Affiliated Hospital of China Medical University, Shenyang 110001, P. R. China.
Shuo ChenDepartment of Gynecology, The First Affiliated Hospital of China Medical University, Shenyang 110001, P. R. China.
Bo-Liang LiuDepartment of Gynecology, The First Affiliated Hospital of China Medical University, Shenyang 110001, P. R. China.
Yang ZhaoDepartment of Gynecology, The First Affiliated Hospital of China Medical University, Shenyang 110001, P. R. China.
First Hospital of China Medical University · CNChina Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

E2F1 (E2F transcription factor 1) can act as a tumor suppressor or oncogene. We report the molecular mechanism of E2F1 in ovarian carcinoma tumorigenesis and progression. E2F1 expression levels in ovarian carcinoma tissue were examined by immunohistochemistry. After E2F1 plasmid transfection and E2F1-microRNA-519d (miR-519d)/si-RhoC (Ras homolog gene family member C) co-transfection, ovarian cancer cell phenotypes and the related molecules were examined in vitro and in vivo. E2F1 was overexpressed in type I and type II ovarian carcinoma as compared to normal ovary tissues and normal fallopian tube tissues, respectively. E2F1 overexpression promoted cell proliferation, G1-S progression, survival, migration, and invasion in vitro; miR-519d or siRhoC co-transfection reversed E2F1 oncogenic effects. E2F1 overexpression promoted tumor growth in vivo; miR-519d overexpression inhibited it. E2F1 overexpression increased RhoC, Bcl-2, cyclin D1, survivin, MMP2 (matrix metalloproteinase 2), MMP9, STAT3 (signal transducer and activator of transcription 3), and HuR (ELAV-like RNA-binding protein 1) expression; miR-519d overexpression decreased their expression. E2F1 downregulated miR-519d directly and miR-519d downregulated RhoC directly. Conversely, miR-519d directly downregulated E2F1, There is a direct repressive regulatory loop between E2F1 and miR-519d. We provide evidence that E2F1/miR-519d/RhoC is a promising signaling pathway for diagnosing and treating ovarian carcinoma.

Indexed as

Gene Expression Regulation, NeoplasticAdolescentAdultAgedAnimalsApoptosisBlotting, WesternCell CycleCell Line, TumorCell MovementCell ProliferationE2F1 Transcription FactorFemaleHumansImmunohistochemistryMice, Inbred BALB CE2F1 protein, humanE2F1 Transcription FactorMicroRNAsMIRN519 microRNA, humanrhoC GTP-Binding ProteinRHOC protein, humanrho GTP-Binding ProteinsE2F1microRNA-519dovarian carcinomaRhoCtumorigenesis and progression

Identifiers

PMID28146423
PMCPMC5362443
OpenAlexW2581700194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.